10x Genomics Statistics
Share Statistics
10x Genomics has 121.05M shares outstanding. The number of shares has increased by 1.58% in one year.
| Shares Outstanding | 121.05M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.47% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 112.84M |
| Failed to Deliver (FTD) Shares | 5.53K |
| FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 6.17M, so 5.1% of the outstanding shares have been sold short.
| Short Interest | 6.17M |
| Short % of Shares Out | 5.1% |
| Short % of Float | 5.47% |
| Short Ratio (days to cover) | 3.09 |
Valuation Ratios
The PE ratio is -25.7 and the forward PE ratio is -12.96.
| PE Ratio | -25.7 |
| Forward PE | -12.96 |
| PS Ratio | 10.6 |
| Forward PS | 2.4 |
| PB Ratio | 8.85 |
| P/FCF Ratio | -101.3 |
| PEG Ratio | n/a |
Enterprise Valuation
10x Genomics Inc. has an Enterprise Value (EV) of 6.29B.
| EV / Earnings | -24.67 |
| EV / Sales | 10.17 |
| EV / EBITDA | -30.68 |
| EV / EBIT | -32.28 |
| EV / FCF | -97.23 |
Financial Position
The company has a current ratio of 4.69, with a Debt / Equity ratio of 0.
| Current Ratio | 4.69 |
| Quick Ratio | 4.11 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -5907.55 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -23.9%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.26% |
| Return on Capital (ROIC) | -23.9% |
| Revenue Per Employee | 491.44K |
| Profits Per Employee | -202.62K |
| Employee Count | 1.26K |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.84 |
Taxes
| Income Tax | 6.34M |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by -69.87% in the last 52 weeks. The beta is 1.87, so 10x Genomics 's price volatility has been higher than the market average.
| Beta | 1.87 |
| 52-Week Price Change | -69.87% |
| 50-Day Moving Average | 15.15 |
| 200-Day Moving Average | 21.36 |
| Relative Strength Index (RSI) | 55.88 |
| Average Volume (20 Days) | 2.09M |
Income Statement
In the last 12 months, 10x Genomics had revenue of 618.73M and earned -255.10M in profits. Earnings per share was -2.18.
| Revenue | 618.73M |
| Gross Profit | 409.31M |
| Operating Income | -194.95M |
| Net Income | -255.10M |
| EBITDA | -205.11M |
| EBIT | -194.95M |
| Earnings Per Share (EPS) | -2.18 |
Balance Sheet
The company has 359.28M in cash and 95.37M in debt, giving a net cash position of 263.91M.
| Cash & Cash Equivalents | 359.28M |
| Total Debt | 95.37M |
| Net Cash | 263.91M |
| Retained Earnings | -1.28B |
| Total Assets | 937.79M |
| Working Capital | 472.66M |
Cash Flow
In the last 12 months, operating cash flow was -15.20M and capital expenditures -49.52M, giving a free cash flow of -64.72M.
| Operating Cash Flow | -15.20M |
| Capital Expenditures | -49.52M |
| Free Cash Flow | -64.72M |
| FCF Per Share | -0.55 |
Margins
Gross margin is 6.62K%, with operating and profit margins of -3.15K% and -4.12K%.
| Gross Margin | 6.62K% |
| Operating Margin | -3.15K% |
| Pretax Margin | -4.02K% |
| Profit Margin | -4.12K% |
| EBITDA Margin | -33.15% |
| EBIT Margin | -31.51% |
| FCF Margin | -10.46% |
Dividends & Yields
TXG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.01% |
| FCF Yield | -3.43% |
Analyst Forecast
The average price target for TXG is $24, which is 54.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $24 |
| Price Target Difference | 54.2% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
Stock Splits
The last stock split was on Jul 17, 2006. It was a backward split with a ratio of 1:2.
| Last Split Date | Jul 17, 2006 |
| Split Type | backward |
| Split Ratio | 1:2 |
Scores
| Altman Z-Score | 3.5 |
| Piotroski F-Score | 5 |